We have updated Dermatitis Drugs Market with respect to COVID-19 Business Impact.
Inquire before buying
This report focuses on the Dermatitis Drugs market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Dermatitis Drugs market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.
Global Dermatitis Drugs Market: Segment Analysis
The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.
Global Dermatitis Drugs Market: Regional Analysis
The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.
Global Dermatitis Drugs Market: Competitive Landscape
This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled
Report Coverage
Atopic Dermatitis is the most common form of dermatitis, affecting around 18 million adults in the U.S. every year. The dermatitis drugs market is expected to progress with a rapid pace in the forecast duration, owing to the introduction of effective therapies at a premium price structure, improved diagnosis of the disease, and rising incidence rate of atopic dermatitis. Although the first line of treatment is usually steroids administration in emerging nations, the patients and physicians are now preferring more specific non-steroid treatment for specific dermatitis type in the developed countries.
The report provides qualitative and quantitative insights on the dermatitis drugs industry and detailed analysis of dermatitis drugs market size and growth rate for all possible segments in the market. The market is segmented on the basis of drug class, disease indication and distribution channel. Based on drug class, the dermatitis market is categorized into corticosteroids, calcineurin Inhibitors, biologics, PDE4 inhibitors, and others.
On the basis of disease indication, the market is classified into atopic dermatitis, contact dermatitis, and others, while various distribution channels covered in the report are hospital pharmacy, retail pharmacy, and online pharmacy. Geographically, the dermatitis drugs market is segmented into four major regions, which are North America, Europe, Asia Pacific, and rest of world. The regions are further categorized into countries.
Along with this, the report provides elaborative analysis of the dermatitis drugs market dynamics and competitive landscape. Various key insights provided in the report are the prevalence of major dermatitis types by key countries, recent industry developments such as partnerships, mergers & acquisitions, pipeline analysis, patent landscape, reimbursement scenario by key countries, and regulatory scenario.
SEGMENTATION
- Drug Class
- Calcineurin Inhibitors
- PDE4 Inhibitors
- Corticosteroids
- Biologics
- Others
By Disease Indication
- Atopic Dermatitis
- Contact Dermatitis
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Key Industry Development
In Aug 2020
, LEO Pharma A/S announced the sale of a portfolio of four non-core products to Cheplapharm for EUR 300 million. The agreement represents a milestone in the roll-out of LEO Pharma’s 2030 strategy which increases the company’s focus on new innovative solutions for medical dermatology.
The divested portfolio comprises four products within bone disorders/nephrology, dermatology and gynecology: One-Alpha©(Alfacalcidol), Locoid©(Cortisol), Pimafucin©(Natamycin), and Zineryt©(Erythromycin 40 mg and Zinc Acetate dihydrate). The annual turnover of the portfolio in 2019 amounted to approximately EUR 110 million.
The transaction is expected to close by December 2020, subject to satisfaction of customary closing conditions, including receipt of regulatory approvals. Following the closing, LEO Pharma and Cheplapharm will work closely together to ensure a smooth and effective transition of the products and business.
By Geography
- North America (USA and Canada)
- Europe (UK, Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
- Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
- Rest of World